Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) EBITDA: 2022-2025

Historic EBITDA for Addex Therapeutics (ADXN) over the last 3 years, with Jun 2025 value amounting to -$2.2 million.

  • Addex Therapeutics' EBITDA fell 115.79% to -$2.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$6.1 million, marking a year-over-year decrease of 119.55%. This contributed to the annual value of -$3.3 million for FY2024, which is 123.29% down from last year.
  • Per Addex Therapeutics' latest filing, its EBITDA stood at -$2.2 million for Q2 2025, which was down 43.11% from -$1.6 million recorded in Q1 2025.
  • In the past 5 years, Addex Therapeutics' EBITDA ranged from a high of $23.4 million in Q4 2023 and a low of -$20.8 million during Q4 2022.
  • Over the past 3 years, Addex Therapeutics' median EBITDA value was -$2.1 million (recorded in 2024), while the average stood at $1.9 million.
  • In the last 5 years, Addex Therapeutics' EBITDA spiked by 553.65% in 2024 and then plummeted by 115.79% in 2025.
  • Addex Therapeutics' EBITDA (Quarterly) stood at -$20.8 million in 2022, then skyrocketed by 212.45% to $23.4 million in 2023, then tumbled by 101.61% to -$377,715 in 2024, then crashed by 115.79% to -$2.2 million in 2025.
  • Its EBITDA stands at -$2.2 million for Q2 2025, versus -$1.6 million for Q1 2025 and -$377,715 for Q4 2024.